Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, October 27, 2026

Back to today

From X

@kevin__mak 6 clicks

Kevin Mak on X

$CMPS Great article this weekend in Politico about psychedelics. There's overwhelming alignment across the government to moving these treatments forward. Given this, I really can't see COMP360 getting ensnared in the approval process, or worse, through reimbursement/REMS bureaucracy once commercialized. At current prices, I believe the market is treating CMPS as a "risky proposition" because historically, that was very true. I think that regime has changed dramatically in the last 12 months. Spend some time talking to an LLM about COMP360 vs Spravato (>$2B/year in sales). Which would you rather take? But even more importantly, Spravato has <5% market share of Treatment Resistant Depression, the other ~95% of patients are generally seeking options. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. --- The VA has led the push in Washington to advance access to psychedelic therapy. It’s involved in 20 psychedelic clinical trials and was one of the first major health care systems to roll out Spravato, an FDA-approved treatment for depression using esketamine, a chemical component found in ketamine. Ketamine — an anesthetic frequently referred to as a psychedelic due to its psychoactive effects — is currently the only psychedelic-like drug approved for medical use. Trump administration officials say they hope more will be approved soon. “We want to see the drug approved if it’s safe and effective, and the reason why is because there’s a mental health crisis,” Matt Zorn, deputy general counsel at the Health and Human Services Department, told POLITICO.

Investor Letters

All letters

Right-Sizing Memory

Micron’s AI memory demand depends on workload-specific accelerator designs that shift bits among HBM, GDDR and LPDDR, changing wafer…

MU $946BNVDA $5.2T
Chipstrat 4 clicks

Are Neoclouds Dead?

Neoclouds face tighter debt financing as AI infrastructure capex outruns cash flow, leaving cash-burning GPU providers more exposed than…

NBIS $42B
Daniel Romero 9 clicks

Reddit: Deep Dive Analysis

Reddit generated $805 million in Q2 2026 revenue, 95% from ads, but slowing Google search referrals expose AI-driven traffic and…

RDDT $18B
Hated Moats 6 clicks

Qualcomm Inc. (QCOM)

Qualcomm supplies chips for on-device AI agents and data center inference, with Meta and AWS agreements expanding its role across both…

QCOM $195B
SixSigmaCapital: Navigating the Financial Markets 5 clicks
WULF · long

Terawulf INC

TeraWulf is shifting from bitcoin mining toward data centers, seeking a higher-quality and more defensive business model.

WULF $5.4B
Value Investors Club

The Data Center Bridge

Small- and mid-cap data center stocks trade as one despite sharply different funding bridges: 12 of 15 cover fixed costs on signed…

IREN $11BFRMI $1.9B
CV's Substack 16 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 67 of 268

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.